ブロンコゲンがんの化学療法. メソトレクサート,ドクソルビシン,サイクロフォスファミド,ロムスティン
JAMA
|May 30, 1977
まとめ
この研究では,メトトレキサート,ドクソルビシン水塩化物,サイクロフォスファミド,ロムスティンの組み合わせであるMACC化学療法が,ステージIIIのブロンコゲン性がん患者で46%の応答率を達成したことを示しています. この治療は,管理可能な毒性を持つすべての癌タイプで生存効果を提供しました.
科学分野:
- 腫瘍学 腫瘍学
- 医療腫瘍学 医療腫瘍学
- 肺内科 肺内科 肺内科
背景:
- Bronchogenic carcinoma,特にステージIIIは,重要な治療上の課題を提示しています.
- ステージIIIの肺がんにおける拡散性疾患は,多くの場合,全身的な治療アプローチを必要とします.
研究 の 目的:
- ステージIIIの Bronchogenic Carcinomaの患者にMACC化学療法療法の有効性と安全性を評価する.
- 異なる組織学的サブタイプにおける応答率と生存結果を評価する.
主な方法:
- ステージIIIのブロンコゲンがん患者41人のコホートは,MACC化学療法 (メソトレキサート,ドクソルビシン水塩化物,サイクロフォスファミド,ロムスティン) を受けました.
- 客観的な応答率と精算学的生存期間の中央値は,プライマリエンドポイントでした.
- 毒性反応は安全性評価のためにモニタリングされた.
主要な成果:
- 患者コホートでは,全体的に46%の客観的な応答率が観察されました.
- 回答は,状細胞癌 (4/10),アデノカルシノーマ (6/17),および小細胞アナプラスティックカルシノーマ (6/7) で記録されました.
- 精算学的生存期間の中央値は9ヶ月で,すべての細胞タイプで生存期間が延長された.
結論:
- MACC化学療法療法は,拡散性疾患を含む第3段階のブロンコゲン性がんにおいて有意な活性を示しています.
- この組み合わせ治療は,組織学的サブタイプに関係なく生存の利点を提供します.
- 観察された中等毒性プロファイルは,外来投与の可行性を支持しています.
さらに関連する動画
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11:17Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
関連する概念動画
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
